Treatment of Clostridium difficile infection presents a unique challenge in patients with cancer. C difficile infections are often related to the use of antibiotics and to hospitalizations, and patients undergoing chemotherapy treatment may be at a particularly high risk for infection.
The Mass General Cancer Center is among the leading cancer care providers in the United States, and is a National Cancer Institute–designated comprehensive cancer center as part of the 7-member Harvard Medical School consortium.
Several studies have shown that Ki67 is an independent prognostic factor in patients with breast cancer, and Ki67 is included in the Oncotype DX test that estimates the likelihood of breast cancer recurrence and the need for chemotherapy.
Inpatient chemotherapy is often considered a financial loss, and according to Ali McBride, PharmD, MS, BCPS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center, Tucson, transitioning chemotherapy to the outpatient setting can be beneficial to patients and providers.